PGL

15th of July 2002



PI-88 Clinical Trials Update [April-June 2002]

In April we announced that the first patients have been enrolled in a Phase II trial of PI-88 in multiple myeloma at The Mater Misericordiae Hospital (Newcastle) and the Wesley Clinic Research Centre (Brisbane). This followed on from the enrolment of the first patient in the trial, Maureen Tilders, at the Alfred Hospital in Melbourne (pictured below with Bone Marrow Transplant Unit Clinical Trials Coordinator Nola Kennedy).

read more



Milestone in Heparanase Drug Design Program

Progen has reached a significant milestone in its program to develop novel drugs to inhibit the enzyme heparanase.

read more



Contract manufacturing agreement with U.S. Biotech
International Recognition of Progen’s cGMP Expertise

In early April we announced a AUD500,000 manufacturing contract with US biotechnology company Lipid Sciences to provide manufacturing and clinical support for their Phase I Clinical Trial.

read more



Progen platform technology development moving forward

Progen has submitted a second provisional specification with the Australian Patent Office titled ‘The process for synthesising C-glycosides’. The inventors, Doctors Martin Banwell and David Armitt from the Australian National University (ANU), were funded through a Progen collaboration with ANU.

read more



On the road .....

In May, Progen’s VP of Business Development, Dr Peter Devine (pictured below with other delegates), attended the 5th Australia-Japan Symposium on Drug Design and Development in Japan. Dr Devine delivered two presentations at the meeting, and participated in a business partnering session with potential Japanese alliance partners. Other highlights of the trip included a networking reception at the Australian Consulate General’s home in Osaka, where many key Japanese pharmaceutical representatives attended. An article on Progen appeared in Japan’s leading economic and business newspaper (Nihon Kensai Shimbun) that has a circulation of over 3 million.

read more



Progen not affected by R&D Start Grant suspension

The Federal Government’s suspension of the Start Grant scheme following a $40 million blow-out this financial year will not affect Progen’s $3 million grant awarded late 2001.

read more



The Progen Investigator
Simplifying the Science

The Progen Investigator is designed to answer your questions about technical related issues. Below are some answers to common questions about PI-88, our lead drug candidate. Please feel free to submit your inquiries to [email protected].

read more



For Further Information

PROGEN e-NEWS aims to keep you informed of significant developments and milestones achieved by Progen Industries Limited. For information about any topics in this newsletter, please contact:

read more

have a good evening